Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study

J Gynecol Oncol. 2017 Jan;28(1):e25. doi: 10.3802/jgo.2017.28.e25.

Authors

Tadaaki Nishikawa¹, Kosei Hasegawa², Akira Yabuno¹, Hiroyuki Yoshida¹, Masanori Yasuda³, Eito Kozawa⁴, Keiichi Fujiwara¹

Affiliations

¹ Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
² Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan. koseih@saitama-med.ac.jp.
³ Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.
⁴ Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Saitama, Japan.

No abstract available

MeSH terms

Aged
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / adverse effects
Carcinosarcoma / diagnostic imaging
Carcinosarcoma / drug therapy*
Female
Humans
Indazoles
Middle Aged
Ovarian Neoplasms / diagnostic imaging
Ovarian Neoplasms / drug therapy*
Pyrimidines / administration & dosage*
Pyrimidines / adverse effects
Sulfonamides / administration & dosage*
Sulfonamides / adverse effects
Tomography, X-Ray Computed
Uterine Neoplasms / diagnostic imaging
Uterine Neoplasms / drug therapy*

Substances

Antineoplastic Agents
Indazoles
Pyrimidines
Sulfonamides
pazopanib